UBS analyst Colin Bristow maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price target from $315 to $314.
UBS Maintains Neutral on Amgen, Lowers Price Target to $314
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.